羟氯喹治疗儿童间质性肺疾病的前瞻性随机对照试验研究方案
本研究为探索性、前瞻性、随机、双盲、安慰剂对照的2a期多国临床试验,旨在评估羟氯喹在儿童间质性肺疾病(chILD)中的疗效与安全性。研究采用START和STOP两个研究模块,分别针对开始和停止羟氯喹治疗的患者,允许交叉设计以纳入不同年龄组患者。这是首个针对chILD药物治疗的国际研究者发起的对照研究。
要点
- chILD罕见且病死率高,目前尚无验证的药物治疗。
- 研究采用START和STOP双模块设计,可分别评估起始和撤药效果。
- 主要纳入遗传、组织学或特发性肺出血诊断的chILD患者。
核心结论
- 本研究旨在评估羟氯喹在儿童间质性肺疾病中的疗效与安全性,为该罕见病提供首个对照性药物治疗证据。
研究设计与样本
- 探索性、前瞻性、随机、双盲、安慰剂对照、平行组、多国2a期临床试验。
- 纳入慢性(≥3周)弥漫性肺实质疾病,经遗传、组织学或特发性肺出血诊断的chILD患者。
- 研究含START和STOP两个模块,可任意顺序启动,每例患者每个模块仅参与一次。
- START模块随机平行治疗4周后将安慰剂组转为活性药物;STOP模块将正在服用羟氯喹者随机分为安慰剂或羟氯喹组。
关键数值与推荐
- START模块治疗4周后安慰剂组转为活性药物。
- 纳入标准要求慢性弥漫性肺实质疾病持续时间≥3周。
临床怎么用
- 该研究为chILD患者使用羟氯喹提供前瞻性对照证据,可能指导临床用药决策。
- 双模块设计允许纳入已超说明书使用羟氯喹的患者,便于评估起始或撤药时机。
局限性
- 研究为探索性2a期试验,样本量未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung diseases in children (chILD) are rare and consist of many different entities that affect the parenchyma of the lungs, leading to a chronic lung disease. The natural course of many of these diseases is connected with a high morbidity and significant mortality. Symptomatic treatment consists of oxygen supplementation, adequate nutrition adapted to the high energy demand generated by the disease due to the increased breathing effort required, as well as immunization against respiratory pathogens to prevent exacerbations through respiratory infections. No proven pharmacological treatments are available to date. This placebo-controlled study aims to evaluate the efficacy and safety of the mid-term use of hydroxychloroquine in chILD. METHODS AND DESIGN: The study is an explorative, prospective, randomized, double-blind, placebo-controlled investigation of hydroxychloroquine (HCQ) in chILD. Patients can be included into the trial when diagnosed with a chronic (≥ 3 weeks' duration) diffuse parenchymal lung disease (chILD) (1) genetically defined, (2) histologically defined or (3) diagnosed with idiopathic pulmonary hemorrhage (hemosiderosis). The study contains of two different study blocks, a START and a STOP block, which can be initiated in any sequence. Each patient can participate in each block only once. In the START block subjects are randomized to parallel groups for 4 weeks treatment, then the placebo group is switched to the active drug. In the STOP block, subjects taking HCQ are randomized into parallel groups treated with placebo or HCQ. DISCUSSION: This study is the first international, investigator-initiated, prospective and controlled investigation of a pharmacological treatment in chILD. The block design was selected as it has the advantage of accommodating patients who are initiating or withdrawing from HCQ therapy, thus allowing the participation of those who were previously started on off-label HCQ. The cross-over design and selected outcome parameters enables us to include appropriate numbers of patients of all age groups from neonates to adults suffering from these rare diseases. TRIAL REGISTRATION: This is an exploratory, Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD. Study title: Hydroxychloroquine in pediatric ILD: START randomized controlled in parallel groups, then switch placebo to the active drug, and STOP randomized controlled in parallel groups to evaluate the efficacy and safety of hydroxychloroquine (HCQ). Short title: HCQ in pediatric ILD, particularly 4surfdefect. EudraCT, ID: 2013-003714-40. Registered on 2 July 2013. ClinicalTrials.gov, ID: NCT02615938. Registered on 8 November 2015. IZKS trial code: 2013-006; Sponsor: University Hospital, Ludwig-Maximilians University of Munich. Responsible Party: Prof. Dr. med. Matthias Griese, University Hospital, Ludwig-Maximilians University of Munich, Germany.
引用
- Griese M, Köhler M, Witt S, et al. Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial. Trials. 2020. PMID: 32245508. doi:10.1186/s13063-020-4188-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。